business
Lucid Capital Markets initiates Adial Pharmaceuticals stock with buy rating on colitis drug potential
Lucid Capital Markets initiates Adial Pharmaceuticals stock with buy rating on colitis drug potential
Read full story on Investing.com → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop